Impact of extranodal disease burden on survival following CAR-T therapy in relapsed/refractory large B-cell lymphoma: A propensity score-matched multi-center analysis.
TL;DR
Overall survival, CRS, ICANS, and sepsis rates were comparable between extranodal and nodal disease cohorts, and CAR-T therapy as equally effective in extranodal involvement should not influence treatment eligibility decisions.
Abstract
640 Background: Extranodal involvement in large B-cell lymphoma (LBCL) has traditionally been associated with more aggressive disease and poorer outcomes with conventional therapies. Whether this adverse prognostic effect persists in the era of chimeric antigen receptor T-cell (CAR-T) therapy remains unclear. We evaluated the impact of extranodal disease on survival and treatment-related toxicities following CAR-T therapy in a large real-world cohort. Methods: Using the TriNetX Global Collaborative Network, we identified adult patients with relapsed/refractory LBCL who underwent CAR-T therapy. Patients were categorized into extranodal LBCL and nodal LBCL cohorts. Propensity score matching (1:1) was performed to balance demographics, comorbidities, and disease-related characteristics. The primary outcome was all-cause mortality. Secondary outcomes included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and sepsis. Kaplan–Meier analyses, hazard ratios, and risk estimates were calculated. Results: After matching, 681 patients were included in each cohort. All-cause mortality occurred in 34.0% of the extranodal group versus 38.6% of the nodal group (RR 0.88, 95% CI 0.76–1.01; p=0.075). Median overall survival was 1,572 days in the extranodal cohort compared with 1,438 days in the nodal cohort, but Kaplan–Meier analysis showed no statistically significant difference (HR 0.92, 95% CI 0.77–1.09; log-rank p=0.334). CRS occurred in 50.1% vs 50.7% (RR 0.99, p=0.839), with no difference in CRS-free survival (HR 0.95, p=0.512). ICANS occurred in 22.8% vs 26.8% (RR 0.85, p=0.115), with no significant difference in ICANS-free survival (HR 0.84, p=0.137). Sepsis rates were similar (22.6% vs 23.4%; RR 0.97, p=0.771), with comparable sepsis-free survival (HR 1.01, p=0.929). Conclusions: In this large, propensity score-matched real-world study, extranodal disease did not adversely impact outcomes following CAR-T therapy in patients with R/R LBCL. Overall survival, CRS, ICANS, and sepsis rates were comparable between extranodal and nodal disease cohorts. Although a numerical trend toward improved survival was observed among patients with extranodal involvement, the difference was not statistically significant. These findings suggest that CAR-T therapy as equally effective in extranodal involvement should not influence treatment eligibility decisions.